What's the difference between Zepbound and Mounjaro?
Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
Zepbound and Mounjaro are both tirzepatide — exactly the same active ingredient made by Eli Lilly. The difference is the FDA-approved indication: Zepbound is approved specifically for chronic weight management, while Mounjaro is approved for type 2 diabetes. Insurance coverage typically follows indication: Mounjaro is more often covered (as a diabetes drug) than Zepbound (as a weight-loss drug). Dosing schedules are nearly identical (2.5mg starting → up to 15mg maintenance, weekly). Some plans cover one and not the other for the same patient; the prescriber chooses based on indication. Mounjaro is sometimes prescribed off-label for weight loss, which insurance generally won't cover. Patients with both indications (T2D + obesity) may have either prescribed depending on which their plan covers preferentially.
Where to start
Licensed US telehealth services that handle this. We may earn a commission when you sign up. See disclosure.
Ro
from $145/mo- Best for insured patients
- Best for clinical oversight
Ro Body — branded GLP-1 weight care program
Hims
from $199/mo- Best for cash-pay
- Best for speed
Hims Weight Loss — compounded GLP-1 from $199/mo
Drugs referenced
Related questions
Wegovy vs Zepbound: which is more effective?
In separate Phase 3 trials, Zepbound (tirzepatide 15mg) produced ~20% mean body weight loss vs Wegovy (semaglutide 2.4mg) at ~15%. A head-to-head trial (SURMOUNT-5) confirmed Zepbound's edge. That said, individual response varies widely: some patients lose more on semaglutide than tirzepatide, others tolerate one's side-effect profile better than the other.